ABBISKO-B (02256) Surges Over 9% Again as Global Phase III MANEUVER Study Results for Beijiemai Published in The Lancet
Stock News
Mar 10
ABBISKO-B (02256) has risen more than 9% again. As of the time of writing, the stock was up 8.76%, trading at HK$12.91 with a turnover of HK$21.9969 million. The company announced that the results of the global multicenter Phase III MANEUVER study for its self-developed novel, oral, highly selective, and potent small molecule CSF-1R inhibitor, Beijiemai (Pimitinib Hydrochloride Capsules, ABSK021), were officially published in the international medical journal The Lancet on March 5. This publication marks a significant milestone for ABBISKO-B, reflecting the quality of clinical research, data integrity, and international academic recognition of this innovative therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.